Inhibition of Glioblastoma Growth by the Thiadiazolidinone Compound TDZD-8

PLoS ONE

Volumn 5, Issue 11, 2010, Pages

  Aguilar Morante, Diana ^a   Morales Garcia, Jose Angel ^a   Sanz Sancristobal, Marina ^a   Garcia Cabezas, Miguel Angel ^c   Santos, Angel ^b   Perez Castillo, Ana ^a  

^a CSIC   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

4 BENZYL 2 METHYL 1,2,4 THIADIAZOLIDINE 3,5 DIONE; EARLY GROWTH RESPONSE FACTOR 1; GLYCOGEN SYNTHASE KINASE 3BETA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P21; S6 KINASE; TDZD 8; THIADIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; 4-BENZYL-2-METHYL-1,2,4-THIADIAZOLIDINE-3,5-DIONE; CASPASE 2; CYCLINE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER STEM CELL; CANCER SURVIVAL; CELL PROLIFERATION; CELL RENEWAL; CONTROLLED STUDY; DRUG EFFECT; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INACTIVATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; ALLOTRANSPLANTATION; ANIMAL; C57BL MOUSE; CANCER TRANSPLANTATION; CELL SURVIVAL; DRUG ANTAGONISM; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALIA; MURINAE;

ANIMALS; APOPTOSIS; CASPASE 2; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; GLIOBLASTOMA; GLYCOGEN SYNTHASE KINASE 3; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM TRANSPLANTATION; NF-KAPPA B; PHOSPHORYLATION; PROLIFERATING CELL NUCLEAR ANTIGEN; THIADIAZOLES; TRANSPLANTATION, HOMOLOGOUS; TUMOR BURDEN;

EID: 78249279372     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013879     Document Type: Article

References (58)

1. De Angelis LM (2001) Brain tumors. N Engl J Med 344: 114-123.
2. Benedetti S, Pirola B, Pollo B, Magrassi L, Bruzzone MG, et al. (2000) Gene therapy of experimental brain tumors using neural progenitor cells. Nat Med 6: 447-450.
3. Fomchenko EI, Holland EC (2006) Mouse models of brain tumors and their applications in preclinical trials. Clin Cancer Res 12: 5288-5297.
4. Jope RS, Johnson GV (2004) The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 29: 95-102.
5. Kim L, Kimmel AR (2000) GSK3, a master switch regulating cell-fate specification and tumorigenesis. Curr Opin Genet Dev 10: 508-514.
6. Kaidanovich O, Eldar-Finkelman H (2002) The role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes. Expert Opin Ther Targets 6: 555-561.
7. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, et al. (2000) Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 406: 86-90.
8. De Ferrari GV, Inestrosa NC (2000) Wnt signaling function in Alzheimer's disease. Brain Res Brain Res Rev 33: 1-12.
9. Sun A, Shanmugam I, Song J, Terranova PF, Thrasher JB, et al. (2007) Lithium suppresses cell proliferation by interrupting E2F-DNA interaction and subsequently reducing S-phase gene expression in prostate cancer. Prostate 67: 976-988.
10. Ghosh JC, Altieri DC (2005) Activation of p53-dependent apoptosis by acute ablation of glycogen synthase kinase-3beta in colorectal cancer cells. Clin Cancer Res 11: 4580-4588.
11. Martinez A, Alonso M, Castro A, Perez C, Moreno FJ (2002) First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J Med Chem 45: 1292-1299.
12. Martinez A, Castro A, Dorronsoro I, Alonso M (2002) GSK-3 inhibitors as promising drugs for the treatment of Alzheimer disease, cancer, diabetes, and inflammation. MedResRev 22: 373-384.
13. Chin PC, Majdzadeh N, D'Mello SR (2005) Inhibition of GSK3beta is a common event in neuroprotection by different survival factors. Brain Res Mol Brain Res 137: 193-201.
14. Dugo L, Abdelrahman M, Murch O, Mazzon E, Cuzzocrea S, et al. (2006) Glycogen synthase kinase-3beta inhibitors protect against the organ injury and dysfunction caused by hemorrhage and resuscitation. Shock 25: 485-491.
15. Cuzzocrea S, Mazzon E, Di Paola R, Muia C, Crisafulli C, et al. (2006) Glycogen synthase kinase-3beta inhibition attenuates the degree of arthritis caused by type II collagen in the mouse. Clin Immunol 120: 57-67.
16. Cuzzocrea S, Genovese T, Mazzon E, Crisafulli C, Di Paola R, et al. (2006) Glycogen synthase kinase-3 beta inhibition reduces secondary damage in experimental spinal cord trauma. J Pharmacol Exp Ther 318: 79-89.
17. Whittle BJ, Varga C, Posa A, Molnar A, Collin M, et al. (2006) Reduction of experimental colitis in the rat by inhibitors of glycogen synthase kinase-3beta. Br J Pharmacol 147: 575-582.
18. Guzman ML, Li X, Corbett CA, Rossi RM, Bushnell T, et al. (2007) Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8). Blood 110: 4436-4444.
19. Edwards E, Geng L, Tan J, Onishko H, Donnelly E, et al. (2002) Phosphatidylinositol 3-kinase/Akt signaling in the response of vascular endothelium to ionizing radiation. Cancer Res 62: 4671-4677.
20. Kjaergaard J, Tanaka J, Kim JA, Rothchild K, Weinberg A, et al. (2000) Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth. Cancer Res 60: 5514-5521.
21. Miyatake S, Martuza RL, Rabkin SD (1997) Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma. Cancer Gene Ther 4: 222-228.
22. Zagzag D, Miller DC, Chiriboga L, Yee H, Newcomb EW (2003) Green fluorescent protein immunohistochemistry as a novel experimental tool for the detection of glioma cell invasion in vivo. Brain Pathol 13: 34-37.
23. Goulet AC, Chigbrow M, Frisk P, Nelson MA (2005) Selenomethionine induces sustained ERK phosphorylation leading to cell-cycle arrest in human colon cancer cells. Carcinogenesis 26: 109-117.
24. Tang D, Wu D, Hirao A, Lahti JM, Liu L, et al. (2002) ERK activation mediates cell cycle arrest and apoptosis after DNA damage independently of p53. J Biol Chem 277: 12710-12717.
25. Tewari R, Sharma V, Koul N, Sen E (2008) Involvement of miltefosinemediated ERK activation in glioma cell apoptosis through Fas regulation. J Neurochem 107: 616-627.
26. Choi BH, Kim CG, Bae YS, Lim Y, Lee YH, et al. (2008) p21 Waf1/Cip1 expression by curcumin in U-87MG human glioma cells: role of early growth response-1 expression. Cancer Res 68: 1369-1377.
27. Wang Z, Zhang B, Wang M, Carr BI (2003) Persistent ERK phosphorylation negatively regulates cAMP response element-binding protein (CREB) activity via recruitment of CREB-binding protein to pp90RSK. J Biol Chem 278: 11138-11144.
28. Roux PP, Richards SA, Blenis J (2003) Phosphorylation of p90 ribosomal S6 kinase (RSK) regulates extracellular signal-regulated kinase docking and RSK activity. Mol Cell Biol 23: 4796-4804.
29. Eldar-Finkelman H (2002) Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol Med 8: 126-132.
30. Kotliarova S, Pastorino S, Kovell LC, Kotliarov Y, Song H, et al. (2008) Glycogen synthase kinase-3 inhibition induces glioma cell death through c- MYC, nuclear factor-kappaB, and glucose regulation. Cancer Res 68: 6643-6651.
31. Collino M, Aragno M, Castiglia S, Tomasinelli C, Thiemermann C, et al. (2009) Insulin reduces cerebral ischemia/reperfusion injury in the hippocampus of diabetic rats: a role for glycogen synthase kinase-3beta. Diabetes 58: 235-242.
32. Gao HK, Yin Z, Zhou N, Feng XY, Gao F, et al. (2008) Glycogen synthase kinase 3 inhibition protects the heart from acute ischemia-reperfusion injury via inhibition of inflammation and apoptosis. J Cardiovasc Pharmacol 52: 286-292.
33. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, et al. (2004) Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 64: 7011-7021.
34. Palmer TD, Willhoite AR, Gage FH (2000) Vascular niche for adult hippocampal neurogenesis. J Comp Neurol 425: 479-494.
35. Singh SK, Clarke ID, Hide T, Dirks PB (2004) Cancer stem cells in nervous system tumors. Oncogene 23: 7267-7273.
36. Taylor MD, Poppleton H, Fuller C, Su X, Liu Y, et al. (2005) Radial glia cells are candidate stem cells of ependymoma. Cancer Cell 8: 323-335.
37. Kong H, Fan Y, Xie J, Ding J, Sha L, et al. (2008) AQP4 knockout impairs proliferation, migration and neuronal differentiation of adult neural stem cells. J Cell Sci 121: 4029-4036.
38. Tan J, Zhuang L, Leong HS, Iyer NG, Liu ET, et al. (2005) Pharmacologic modulation of glycogen synthase kinase-3beta promotes p53-dependent apoptosis through a direct Bax-mediated mitochondrial pathway in colorectal cancer cells. Cancer Res 65: 9012-9020.
39. Zhou Y, Uddin S, Zimmerman T, Kang JA, Ulaszek J, et al. (2008) Growth control of multiple myeloma cells through inhibition of glycogen synthase kinase-3. Leuk Lymphoma 49: 1945-1953.
40. Ma C, Bower KA, Chen G, Shi X, Ke ZJ, et al. (2008) Interaction between ERK and GSK3beta mediates basic fibroblast growth factor-induced apoptosis in SK-N-MC neuroblastoma cells. J Biol Chem 283: 9248-9256.
41. Luna-Medina R, Cortes-Canteli M, Alonso M, Santos A, Martinez A, et al. (2005) Regulation of Inflammatory Response in Neural Cells in Vitro by Thiadiazolidinones Derivatives through Peroxisome Proliferator-activated Receptor {gamma} Activation. J Biol Chem 280: 21453-21462.
42. Luna-Medina R, Cortes-Canteli M, Sanchez-Galiano S, Morales-Garcia JA, Martinez A, et al. (2007) NP031112, a thiadiazolidinone compound, prevents inflammation and neurodegeneration under excitotoxic conditions: potential therapeutic role in brain disorders. The Journal of neuroscience 27: 5766-5776.
43. Takada Y, Fang X, Jamaluddin MS, Boyd DD, Aggarwal BB (2004) Genetic deletion of glycogen synthase kinase-3beta abrogates activation of IkappaBalpha kinase, JNK, Akt, and p44/p42 MAPK but potentiates apoptosis induced by tumor necrosis factor. J Biol Chem 279: 39541-39554.
44. Deng J, Xia W, Miller SA, Wen Y, Wang HY, et al. (2004) Crossregulation of NF-kappaB by the APC/GSK-3beta/beta-catenin pathway. Mol Carcinog 39: 139-146.
45. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, et al. (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63: 5821-5828.
46. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, et al. (2004) Identification of human brain tumour initiating cells. Nature 432: 396-401.
47. Sanai N, Alvarez-Buylla A, Berger MS (2005) Neural stem cells and the origin of gliomas. N Engl J Med 353: 811-822.
48. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, et al. (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756-760.
49. Phillips TM, McBride WH, Pajonk F (2006) The response of CD24(-/low)/ CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 98: 1777-1785.
50. Woodward WA, Chen MS, Behbod F, Alfaro MP, Buchholz TA, et al. (2007) WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci U S A 104: 618-623.
51. Paxinos G, Franklin K (2001) The mouse brain in stereotaxic coordinates. San Diego: Academic Press.
52. Hennig J, Nauerth A, Friedburg H (1986) RARE imaging: a fast imaging method for clinical MR. Magn Reson Med 3: 823-833.
53. Bottomley PA (1987) Spatial localization in NMR spectroscopy in vivo. Ann N Y Acad Sci 508: 333-348.
54. Tkac I, Starcuk Z, Choi IY, Gruetter R (1999) In vivo 1H NMR spectroscopy of rat brain at 1 ms echo time. Magn Reson Med 41: 649-656.
55. El Andaloussi A, Sonabend AM, Han Y, Lesniak MS (2006) Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors. Glia 54: 526-535.
56. Kim SD, Yang SI, Kim HC, Shin CY, Ko KH (2007) Inhibition of GSK-3beta mediates expression of MMP-9 through ERK1/2 activation and translocation of NF-kappaB in rat primary astrocyte. Brain Res 1186: 12-20.
57. Cortes-Canteli M, Wagner M, Ansorge W, Perez-Castillo A (2004) Microarray analysis supports a role for ccaat/enhancer-binding protein-beta in brain injury. J Biol Chem 279: 14409-14417.
58. Pignatelli M, Sanchez-Rodriguez J, Santos A, Perez-Castillo A (2005) 15-Deoxy-{Delta}-12,14-prostaglandin J2 induces programmed cell death of breast cancer cells by a pleiotropic mechanism. Carcinogenesis 26: 81-92.